Drug class
Nitrogen-free bisphosphonate; inhibitor of osteoclast-mediated bone resorption
Mechanism of action
Adsorbs to hydroxyapatite in bone and is taken up by osteoclasts, impairing osteoclast function and reducing bone resorption. Unlike nitrogen-containing bisphosphonates, it does not act through farnesyl-pyrophosphate synthase inhibition.
General use cases
- Treatment of Paget’s disease of bone and selected metabolic bone disorders, including osteogenesis imperfecta or complex regional pain syndrome in countries where neridronate is authorised.
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
